Neutraceuticals are linked to cure for diseases and delivering these in nanoparticulate form offers a solution to improve their stability and bioavailability. An attempt was made to formulate and evaluate a solid lipid nanoparticulate (SLN) drug delivery system (DDS) of Chlorella pyrenoidosa (CP) in order to improve the bio-accessibility of lipid soluble antioxidant β Carotene present within and check for its anticancer activity. CP containing SLN were formulated with Dynasan 118 (solid lipid), Poloxomer 188 and L-α-Phosphatidylcholine as stabilizers using hot high shear homogenization and ultrasonication. The SLNs were evaluated for appearance, % Entrapment Efficiency (%EE), in-vitro drug release (%DR), particle size (PS), zeta potential (ZP), Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD) and Fourier transformer Infra Red Spectroscopy (FTIR). The anticancer activity of CP and optimized batch of SLNs were evaluated using in-vitro cytotoxicity assessment on human cancer cell lines, MCF-7 and SiHa respectively with positive results. The optimized batch exhibited % EE of 80.52 ± 0.04 % and β carotene release 77.104 ± 0.062 % respectively at the end of 48 hours. SEM studies revealed spherical SLN with smooth surface. DSC, PXRD and FTIR results exhibit the entrapment of CP in SLN. The drug release was found to be higher as compared to its CP suspension. SLNs presented a mean PS of 292.2 nm and ZP-22.9 mV respectively. The results indicate an alternate DDS for increasing the bio-accessibility of natural antioxidant β Carotene present in CP by formulating its SLN.
Loading....